BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, Murray J, Birnkrant D. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-1455.e2. [PMID: 23470616 DOI: 10.1053/j.gastro.2013.02.039] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Nishikawa H, Enomoto H, Nasu A, Aizawa N, Saito M, Tamori A, Kawada N, Kimura T, Osaki Y, Nishiguchi S. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy: IP-10 in telaprevir-based triple therapy. Hepatol Res 2014;44:E397-407. [DOI: 10.1111/hepr.12326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
2 Christensen S, Gillessen A. Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection. Infect Agent Cancer. 2014;9:10. [PMID: 24650206 DOI: 10.1186/1750-9378-9-10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Feeney ER, Chung RT. The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. Dig Dis Sci 2015;60:2232-5. [PMID: 26072321 DOI: 10.1007/s10620-015-3748-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75. [PMID: 25065960 DOI: 10.1111/apt.12871] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
5 Matsuda T, Mccombs JS, Tonnu-mihara I, Mcginnis J, Fox DS. The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration. Forum for Health Economics and Policy 2016;19:333-51. [DOI: 10.1515/fhep-2015-0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ali S, Ali M, Paudyal V, Rasheed F, Ullah S, Haque S, Ur-Rehman T. A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients. Patient Prefer Adherence 2019;13:2089-100. [PMID: 31997877 DOI: 10.2147/PPA.S224937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol 2016;15:333-49. [PMID: 27049487 DOI: 10.5604/16652681.1198803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
9 Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73. [PMID: 24918116 DOI: 10.1586/14787210.2014.929497] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
10 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
11 Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds K, Sinha V. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther 2015;98:394-402. [DOI: 10.1002/cpt.185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
12 Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014;60:748-756. [PMID: 24362076 DOI: 10.1016/j.jhep.2013.12.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
13 Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564-572. [PMID: 25895428 DOI: 10.1016/j.jhep.2015.04.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 15.1] [Reference Citation Analysis]
14 Wysocki J, Newby C, Balart L, Shores N. HCV Triple Therapy is Equally effective in African-Americans and Non-African-Americans. J Racial and Ethnic Health Disparities 2014;1:319-25. [DOI: 10.1007/s40615-014-0039-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6. [PMID: 28486403 DOI: 10.3390/biology6020030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 (Rob) Aggarwal S. A survey of breakthrough therapy designations. Nat Biotechnol 2014;32:323-30. [DOI: 10.1038/nbt.2864] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
17 Martel-Laferrière V, Dieterich DT. Treating HCV in HIV 2013: on the cusp of change. Liver Int 2014;34 Suppl 1:53-9. [PMID: 24373079 DOI: 10.1111/liv.12396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Doyle JS, Thompson AJ, Higgs P, Stoove M, Dietze PM, Hellard ME. New hepatitis C antiviral treatments eliminate the virus. Lancet 2017;390:358-9. [PMID: 28689663 DOI: 10.1016/S0140-6736(17)31817-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39:478-87. [PMID: 24387618 DOI: 10.1111/apt.12601] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 11.5] [Reference Citation Analysis]
21 Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 2014;7:555-66. [PMID: 24918162 DOI: 10.1586/17512433.2014.928196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
22 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015;42:829-844. [PMID: 26238707 DOI: 10.1111/apt.13342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
23 Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol 2016;31:872-82. [PMID: 26514998 DOI: 10.1111/jgh.13223] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
24 Hale AJ, Mathur S, Dejace J, Lidofsky SD. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont. Public Health Rep 2022;:333549221077070. [PMID: 35264027 DOI: 10.1177/00333549221077070] [Reference Citation Analysis]
25 Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B, Dentone C, Nicolini LA, Cassola G, Di Biagio A. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon Outcomes Res 2016;8:15-21. [PMID: 26770065 DOI: 10.2147/CEOR.S93641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Khan MQ, Moreno AD, Joseph N, Kim G, Fimmel CJ. Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis. ACG Case Rep J 2017;4:e21. [PMID: 28184378 DOI: 10.14309/crj.2017.21] [Reference Citation Analysis]
27 Agarwal K, Barnabas A. Faldaprevir for the treatment of genotype-1 hepatitis C virus. Expert Rev Gastroenterol Hepatol 2015;9:277-88. [PMID: 25633983 DOI: 10.1586/17474124.2015.1001742] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Dobler CC, Morgan RL, Falck-Ytter Y, Montori VM, Murad MH. Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evid Based Med 2018;23:50-3. [PMID: 29595129 DOI: 10.1136/bmjebm-2017-110852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719-728. [PMID: 24666106 DOI: 10.1517/13543784.2014.902049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
30 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
31 Domínguez-domínguez L, Bisbal O, Matarranz M, Lagarde M, Pinar Ó, Hernando A, Lumbreras C, Rubio R, Pulido F. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection. Eur J Clin Microbiol Infect Dis 2019;38:725-34. [DOI: 10.1007/s10096-019-03488-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour J, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Kukolj G, Datsenko Y, Garcia M, Scherer J, Quinson A, Stern JO. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Journal of Hepatology 2015;62:1246-55. [DOI: 10.1016/j.jhep.2014.12.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
33 Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs: HEPATOLOGY, Vol. XX, No. X, 2015. Hepatology 2015;62:1298-303. [DOI: 10.1002/hep.27880] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
34 Hsieh YH, Signer D, Patel AV, Viertel V, Saheed M, Irvin R, Sulkowski MS, Thomas DL, Rothman RE. Advanced liver fibrosis and care continuum in emergency department patients with chronic hepatitis C. Am J Emerg Med 2019;37:286-90. [PMID: 30409463 DOI: 10.1016/j.ajem.2018.08.067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Whiteley D, Elliott L, Cunningham-burley S, Whittaker A. Health-Related Quality of Life for individuals with hepatitis C: A narrative review. International Journal of Drug Policy 2015;26:936-49. [DOI: 10.1016/j.drugpo.2015.04.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
36 Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93-103. [PMID: 24206566 DOI: 10.1111/apt.12546] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
37 Lam JT, Salazar L. New combination antiviral for the treatment of hepatitis C. Am J Health Syst Pharm 2016;73:1042-50. [PMID: 27217519 DOI: 10.2146/ajhp150163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Dammacco F, Lauletta G, Vacca A. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med. [DOI: 10.1007/s10238-022-00808-1] [Reference Citation Analysis]
39 Liu X, Wang Y, Zhang G, Li N, Zhu Q, Chang H, Han Q, Lv Y, Liu Z. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. Int J Antimicrob Agents. 2014;44:145-151. [PMID: 25034873 DOI: 10.1016/j.ijantimicag.2014.04.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
40 Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis 2015;60:608-10. [PMID: 25365973 DOI: 10.1093/cid/ciu865] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
41 Yancey A, Armbruster A, Tackett S. Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection. J Pharm Technol 2015;31:29-37. [PMID: 34860883 DOI: 10.1177/8755122514548897] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
42 Kanda T, Nakamoto S, Sasaki R, Nakamura M, Yasui S, Haga Y, Ogasawara S, Tawada A, Arai M, Mikami S. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int J Med Sci. 2016;13:310-315. [PMID: 27076789 DOI: 10.7150/ijms.14953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
43 Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther 2019;17:311-25. [PMID: 30856022 DOI: 10.1080/14787210.2019.1588112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
44 Alqahtani S, Sulkowski M. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. Gastroenterol Clin North Am. 2015;44:825-843. [PMID: 26600222 DOI: 10.1016/j.gtc.2015.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
45 Childs-Kean LM, Hand EO. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin Ther. 2015;37:243-267. [PMID: 25601269 DOI: 10.1016/j.clinthera.2014.12.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
46 Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9:161-173. [PMID: 25788194 DOI: 10.1007/s12072-014-9606-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
47 Chan J. Hepatitis C. Dis Mon 2014;60:201-12. [PMID: 24863270 DOI: 10.1016/j.disamonth.2014.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Fazel Y, Lam B, Golabi P, Younossi Z. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf. 2015;14:1317-1326. [PMID: 26043900 DOI: 10.1517/14740338.2015.1053868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
49 Druyts E, Lorenzi M, Toor K, Thorlund K, Mills EJ. Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM 2015;108:299-306. [PMID: 25239762 DOI: 10.1093/qjmed/hcu202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Taddei TH, Lo Re V 3rd, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Curr HIV/AIDS Rep 2016;13:269-78. [PMID: 27614654 DOI: 10.1007/s11904-016-0327-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
51 Gottlieb RL, Hall SA. The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients. Curr Transplant Rep 2018;5:145-52. [PMID: 29774177 DOI: 10.1007/s40472-018-0192-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Kyle RP, Moodie EE, Klein MB, Abrahamowicz M. Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. Am J Epidemiol 2016;184:249-58. [PMID: 27416840 DOI: 10.1093/aje/kww068] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
53 Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings. J Viral Hepat 2018;25:1472-80. [PMID: 30047625 DOI: 10.1111/jvh.12975] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
54 Bach TA, Zaiken K. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. Am J Health Syst Pharm 2017;74:S1-9. [PMID: 28213381 DOI: 10.2146/ajhp160567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Schiffer JT, Johnston C, Wald A, Corey L. An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infect Dis 2020;7:ofaa232. [PMID: 32661497 DOI: 10.1093/ofid/ofaa232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
56 Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553-561. [PMID: 28634198 DOI: 10.1136/gutjnl-2017-313983] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 13.2] [Reference Citation Analysis]
57 Gentile I, Buonomo AR, Zappulo E, Coppola N, Borgia G. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12:1179-86. [PMID: 25096404 DOI: 10.1586/14787210.2014.945432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
58 Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37:698-708. [PMID: 26047942 DOI: 10.1007/s11096-015-0144-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
59 Rose L, Bias TE, Mathias CB, Trooskin SB, Fong JJ. Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. Ann Pharmacother. 2014;48:1019-1029. [PMID: 24811396 DOI: 10.1177/1060028014534194] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
60 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
61 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
62 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
63 Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
64 Forman MS, Valsamakis A. Hepatitis C Virus. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1599-616. [DOI: 10.1128/9781555817381.ch92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61:41-45. [PMID: 25314116 DOI: 10.1002/hep.27366] [Cited by in Crossref: 118] [Cited by in F6Publishing: 111] [Article Influence: 14.8] [Reference Citation Analysis]
66 Garbuglia AR, Visco-Comandini U, Lionetti R, Lapa D, Castiglione F, D'Offizi G, Taibi C, Montalbano M, Capobianchi MR, Paci P. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. PLoS One 2016;11:e0158989. [PMID: 27560794 DOI: 10.1371/journal.pone.0158989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
67 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
68 Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015;60:1045-51. [DOI: 10.1007/s10620-015-3621-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
69 Wyles DL, Rodriguez-torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, Mchutchison JG, Habersetzer F, Sulkowski MS. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology 2014;60:56-64. [DOI: 10.1002/hep.27053] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
70 Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. J Comp Eff Res 2016;5:129-39. [PMID: 26390233 DOI: 10.2217/cer.15.49] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
71 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
72 Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol 2017;11:85-93. [PMID: 27500437 DOI: 10.1080/17474124.2016.1222271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
73 Gentile I, Borgia G. A pill a day keeps HCV away. Lancet Infect Dis 2015;15:616-7. [PMID: 25863561 DOI: 10.1016/S1473-3099(15)70127-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
75 Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 2016;176:65-73. [PMID: 26595724 DOI: 10.1001/jamainternmed.2015.6011] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 15.7] [Reference Citation Analysis]
76 Domínguez-Domínguez L, Lagarde M, Bisbal O, Matarranz M, Rubio R, Pulido F. Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38:275-8. [PMID: 31668860 DOI: 10.1016/j.eimc.2019.07.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Sarrazin C, Isakov V, Svarovskaia ES, Hedskog C, Martin R, Chodavarapu K, Brainard DM, Miller MD, Mo H, Molina JM, Sulkowski MS. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. Clin Infect Dis 2017;64:44-52. [PMID: 27737953 DOI: 10.1093/cid/ciw676] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
78 Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
79 Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc 2018;21. [PMID: 29314670 DOI: 10.1002/jia2.25059] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
80 Yeung MW, Young J, Moodie E, Rollet-kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull M, Walmsley S, Klein MB; For the Canadian Coinfection Cohort Study Investigators. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clinical Trials 2015;16:100-10. [DOI: 10.1179/501100000024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
81 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
82 Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value Health 2018;21:921-30. [PMID: 30098669 DOI: 10.1016/j.jval.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
84 Rochlani Y, Diab K, Jorde UP. Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities. Curr Heart Fail Rep 2020;17:106-15. [PMID: 32474734 DOI: 10.1007/s11897-020-00466-y] [Reference Citation Analysis]
85 Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015;22:882-9. [PMID: 25847572 DOI: 10.1111/jvh.12409] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
86 Toussaint-Miller KA, Andres J. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Ann Pharmacother 2015;49:1015-30. [PMID: 26139639 DOI: 10.1177/1060028015592015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
87 Duke ER, Williamson BD, Borate B, Golob JL, Wychera C, Stevens-Ayers T, Huang ML, Cossrow N, Wan H, Mast TC, Marks MA, Flowers ME, Jerome KR, Corey L, Gilbert PB, Schiffer JT, Boeckh M. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. J Clin Invest 2021;131:133960. [PMID: 32970635 DOI: 10.1172/JCI133960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
88 Thokala P, Simpson EL, Tappenden P, Stevens JW, Dickinson K, Ryder S, Harrison P. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. Pharmacoeconomics 2016;34:741-50. [PMID: 26892974 DOI: 10.1007/s40273-016-0387-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
89 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
90 Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23:1211-1223. [PMID: 24848437 DOI: 10.1517/13543784.2014.921680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
91 Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 2015;13:198. [PMID: 26289050 DOI: 10.1186/s12916-015-0440-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
92 Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int 2016;10:616-23. [PMID: 27026431 DOI: 10.1007/s12072-016-9719-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
93 Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F, Asociación Castellano y Leonesa de Hepatología (ACyLHE). Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017; 8(2): 137-146 [PMID: 28533924 DOI: 10.4292/wjgpt.v8.i2.137] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
94 Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107-116. [PMID: 28797497 DOI: 10.1016/j.drugpo.2017.07.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]
95 Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther 2015;32:1117-27. [PMID: 26538232 DOI: 10.1007/s12325-015-0258-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
96 Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. J Gastroenterol Hepatol 2017;32:1136-42. [PMID: 27869323 DOI: 10.1111/jgh.13652] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
97 Younossi ZM, Stepanova M, Jacobson IM, Asselah T, Gane EJ, Lawitz E, Foster GR, Roberts SK, Thompson AJ, Willems BE, Welzel TM, Pearlman B, Younossi I, Racila A, Henry L. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther 2018;47:259-67. [DOI: 10.1111/apt.14423] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
98 Vaghi G, Gori B, Strigaro G, Burlone M, Minisini R, Barbaglia MN, Brigatti E, Varrasi C, Pirisi M, Cantello R. Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study. J Neurovirol. 2020;26:870-879. [PMID: 32910431 DOI: 10.1007/s13365-020-00904-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
99 Quigley JM, Bryden PA, Scott DA, Kuwabara H, Cerri K. Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis. Hepatol Res 2015;45:E89-98. [PMID: 25559771 DOI: 10.1111/hepr.12467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
100 Burman BE, Kwo PY, Kowdley KV. Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. Hepatol Int 2014;8:352-64. [DOI: 10.1007/s12072-014-9552-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Johannesen L, Vicente J, Gray RA, Galeotti L, Loring Z, Garnett CE, Florian J, Ugander M, Stockbridge N, Strauss DG. Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science. Clin Pharmacol Ther 2013;95:501-8. [DOI: 10.1038/clpt.2013.238] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 7.7] [Reference Citation Analysis]
102 Tao T, Jiang X, Chen Y, Song Y. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Int J Infect Dis 2017;55:56-71. [PMID: 28040553 DOI: 10.1016/j.ijid.2016.12.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
103 Smith MA, Chan J, Mohammad RA. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann Pharmacother 2015;49:343-50. [PMID: 25515863 DOI: 10.1177/1060028014563952] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
104 Gray E, O'Leary A, Bergin C, Cannon M, Courtney G, Crosbie O, De Gascun CF, Fanning LJ, Feeney E, Houlihan DD, Kelleher B, Lambert JS, Lee J, Mallon P, McConkey S, McCormick A, McKiernan S, McNally C, Murray F, Sheehan G, Stewart S, Walsh C, Norris S; Irish Hepatitis C Outcomes and Research Network (ICORN). Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Rev Gastroenterol Hepatol 2017;11:593-601. [PMID: 28276815 DOI: 10.1080/17474124.2017.1292850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol. 2014;7:131-140. [PMID: 24790644 DOI: 10.1177/1756283x13515825] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 7.1] [Reference Citation Analysis]
106 Hellard ME, Doyle JS. Interferon-free hepatitis C treatment: one pill to fit all? Lancet 2014;383:491-2. [PMID: 24209978 DOI: 10.1016/S0140-6736(13)62151-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
107 Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 17.8] [Reference Citation Analysis]
108 Cooke GS, Pett S, Mccabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch’ng CL, Stone B, Wiselka M, Forton D, Mcpherson S, Halford R, Nguyen D, Smith D, Ansari MA, Ainscough H, Dennis E, Hudson F, Barnes EJ, Walker AS; the STOP-HCV trial team. Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy Mech Eval 2021;8:1-90. [DOI: 10.3310/eme08170] [Reference Citation Analysis]
109 Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AYM, Dinubile MJ, Robertson MN, Wahl J, Barr E, Forns X. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1. Clin Infect Dis 2015;62:32-6. [DOI: 10.1093/cid/civ722] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 10.9] [Reference Citation Analysis]
110 Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 2014;59:3043-52. [PMID: 25102983 DOI: 10.1007/s10620-014-3294-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]